Brazil Antibody Drug Conjugates Market Size & Outlook
Brazil antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
Brazil antibody drug conjugates market highlights
- The Brazil antibody drug conjugates market generated a revenue of USD 39.3 million in 2021 and is expected to reach USD 226.3 million by 2030.
- The Brazil market is expected to grow at a CAGR of 21.5% from 2022 to 2030.
- In terms of segment, blood cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 39.3 million |
| Market revenue in 2030 | USD 226.3 million |
| Growth rate | 21.5% (CAGR from 2021 to 2030) |
| Largest segment | Blood cancer |
| Fastest growing segment | Blood Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, Brazil accounted for 0.7% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in Latin America and is projected to reach USD 110.4 million by 2030.
Blood cancer was the largest segment with a revenue share of 57.25% in 2021. Horizon Databook has segmented the Brazil antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil is expected to witness significant market growth owing to increase in ADC research activities conducted by organizations, such as AC Camargo Cancer Center. It has a free, decentralized universal healthcare system funded by tax revenue from the federal, state, & municipal governments, which is utilized by ~75% of its population for services including oncology.
Adcetris, which is intended for patients with relapsed or refractory Hodgkin’s lymphoma after stem cell therapy, was included in the list of approved drugs by Brazil’s Unified Health System - The Sistema Único de Saúde, in 2019.
Among the leading forms of cancer, prostate and breast cancers were the most prevalent ones. Moreover, the number of cancer cases is predicted to grow by ~50% by 2025, mainly due to a growth in population, especially the geriatric population.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Brazil antibody drug conjugates market size, by application, 2018-2030 (US$M)
Brazil Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
